

# Stefan James

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12089458/publications.pdf>

Version: 2024-02-01

109  
papers

41,092  
citations

41344

49  
h-index

25787

108  
g-index

114  
all docs

114  
docs citations

114  
times ranked

28227  
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	2.2	7,100
2	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	27.0	6,019
3	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	2.2	4,210
4	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
5	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	2.2	2,649
6	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	2.8	2,558
7	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	2.2	2,447
8	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
9	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	27.0	918
10	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017, 389, 1025-1034.	13.7	840
11	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. <i>Lancet, The</i> , 2010, 376, 1320-1328.	13.7	709
12	Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. <i>Circulation</i> , 2006, 114, 1955-1961.	1.6	666
13	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. <i>Lancet, The</i> , 2010, 375, 283-293.	13.7	624
14	Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2010, 122, 2131-2141.	1.6	474
15	Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 38, S1-S52.	1.4	405
16	Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation</i> , 2011, 124, 544-554.	1.6	397
17	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2010, 31, 3006-3016.	2.2	389
18	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. <i>Circulation</i> , 2010, 122, 1056-1067.	1.6	354

#	ARTICLE	IF	CITATIONS
19	International Expert Consensus on Switching Platelet P2Y <sub>12</sub> Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
20	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. <i>European Heart Journal</i> , 2014, 35, 1957-1970.	2.2	275
21	Randomized Comparison of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation in Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting. <i>Circulation</i> , 2011, 123, 79-86.	1.6	269
22	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	1.4	261
23	Thrombus Aspiration in ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2017, 135, 143-152.	1.6	233
24	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 377, 1132-1142.	27.0	228
25	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 73, 741-754.	2.8	218
26	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. <i>Europace</i> , 2019, 21, 192-193.	1.7	209
27	Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 680-688.	2.2	198
28	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. <i>European Heart Journal</i> , 2015, 36, 2608-2620.	2.2	187
29	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013, 34, 1670-1680.	2.2	175
30	Long-Term Results After Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2013, 62, 30-34.	2.8	168
31	A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary) Tj ETQq1 1 0.784314 rgBT/Overlo 2014. 35. 2021-2031. 2.2 148	2.2	148
32	Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial. <i>European Heart Journal</i> , 2012, 33, 3105-3113.	2.2	119
33	The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and) Tj ETQq1 1 0.784314 rgBT/Overlo 2.2 148	2.2	148
34	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDHEART registry 1995 to 2014. <i>European Heart Journal</i> , 2018, 39, 3766-3776.	2.2	112
35	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>European Heart Journal</i> , 2020, 41, 1839-1851.	2.2	106
36	Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016, 387, 136-145.	13.7	96

#	ARTICLE	IF	CITATIONS
37	Comparative Efficacy and Safety of Oral P2Y <sub>12</sub> Inhibitors in Acute Coronary Syndrome. <i>Circulation</i> , 2020, 142, 150-160.	1.6	93
38	A Global Risk Approach to Identify Patients With Left Main or 3-Vessel Disease Who Could Safely and Efficaciously Be Treated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 606-617.	2.9	91
39	Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2713-2723.	2.8	88
40	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	13.7	87
41	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1623-1630.	2.8	80
42	Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2011, 32, 2989-2997.	2.2	71
43	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	13.7	71
44	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020, 51, 3504-3513.	2.0	67
45	External Validation of the DAPT Score in a Nationwide Population. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1069-1078.	2.8	63
46	Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization. <i>Circulation</i> , 2016, 133, 39-47.	1.6	58
47	Safety in simple versus complex stenting of coronary artery bifurcation lesions. The Nordic Bifurcation Study 14-month follow-up results. <i>EuroIntervention</i> , 2008, 4, 229-233.	3.2	56
48	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2012, 164, 334-342.e1.	2.7	53
49	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. <i>American Heart Journal</i> , 2019, 209, 97-105.	2.7	53
50	Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2014, 35, 969-978.	2.2	46
51	β-blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	46
52	Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). <i>Heart</i> , 2011, 97, 1484-1488.	2.9	44
53	Cardiac troponin I levels in patients with non-ST-elevation acute coronary syndrome—The importance of gender. <i>American Heart Journal</i> , 2014, 168, 317-324.e1.	2.7	44
54	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1447-1456.	2.9	41

#	ARTICLE	IF	CITATIONS
55	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 777-787.	2.8	39
56	The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2011, 105, 760-762.	3.4	33
57	An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 53-61.	2.7	33
58	Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction—a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). <i>American Heart Journal</i> , 2016, 175, 36-46.	2.7	31
59	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016, 174, 120-128.	2.7	29
60	The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. <i>International Journal of Stroke</i> , 2019, 14, 745-751.	5.9	28
61	Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration. <i>European Heart Journal</i> , 2018, 39, 2472-2479.	2.2	27
62	Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 151-157.	3.0	27
63	Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. <i>Cmaj</i> , 2012, 184, 1135-1142.	2.0	26
64	Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 218-228.	1.8	26
65	Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force. <i>European Heart Journal</i> , 2018, 39, 4239-4242.	2.2	25
66	Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 203, 697-701.	1.7	24
67	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1171-1189.	2.4	23
68	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	2.2	22
69	Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. <i>Clinical Research in Cardiology</i> , 2018, 107, 816-823.	3.3	21
70	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016, 181, 92-100.	2.7	20
71	Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3039.	2.4	18
72	Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR). <i>European Heart Journal</i> , 2019, 40, 2607-2615.	2.2	17

#	ARTICLE	IF	CITATIONS
73	Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-segment Elevation Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	16
74	Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007381.	3.9	16
75	Radial artery access is associated with lower mortality in patients undergoing primary PCI: a report from the SWEDEHEART registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 323-332.	1.0	16
76	Development and validation of an artificial neural network algorithm to predict mortality and admission to hospital for heart failure after myocardial infarction: a nationwide population-based study. <i>The Lancet Digital Health</i> , 2022, 4, e37-e45.	12.3	16
77	Gender differences in utilization of coronary angiography and angiographic findings after out-of-hospital cardiac arrest: A registry study. <i>Resuscitation</i> , 2019, 143, 189-195.	3.0	15
78	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. <i>Cardiovascular Research</i> , 2019, 115, 1512-1518.	3.8	15
79	The Analgesic Effect of Oxygen in Suspected Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1590-1597.	2.9	13
80	Treatment, Outcomes, Costs, and Quality of Life of Women and Men With Acute Coronary Syndromes Who Have Undergone Percutaneous Coronary Intervention: Results From the Antiplatelet Therapy Observational Registry. <i>Postgraduate Medicine</i> , 2013, 125, 100-107.	2.0	12
81	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
82	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APIxaban for PREvention of Acute ISchemic Events 2 trial. <i>American Heart Journal</i> , 2015, 169, 531-538.	2.7	9
83	Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008671.	3.9	9
84	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017, 130, 1170-1176.	1.5	8
85	Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 492-501.	1.0	8
86	Oxygen therapy in suspected acute myocardial infarction and concurrent normoxemic chronic obstructive pulmonary disease: a prespecified subgroup analysis from the DETO2X-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 984-992.	1.0	8
87	Income is associated with the probability to receive early coronary angiography after out-of-hospital cardiac arrest. <i>Resuscitation</i> , 2020, 156, 35-41.	3.0	8
88	Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention—A case-control study. <i>American Heart Journal</i> , 2011, 162, 363-371.	2.7	7
89	Which Antiplatelet Agent for Whom? Which Patient Populations Benefit Most from Novel Antiplatelet Agents (Ticagrelor, Prasugrel)?. <i>Current Cardiology Reports</i> , 2012, 14, 486-492.	2.9	7
90	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020, 27, 661-676.	1.2	7

#	ARTICLE	IF	CITATIONS
91	Bivalirudin Versus Heparin Monotherapy in ST-Segmentâ€“Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e008969.	3.9	7
92	Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy. <i>American Journal of Medicine</i> , 2013, 126, 723-729.e1.	1.5	6
93	Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. <i>Current Atherosclerosis Reports</i> , 2021, 23, 77.	4.8	6
94	Bleeding associated with the management of acute coronary syndromes. <i>Heart</i> , 2017, 103, 546-562.	2.9	5
95	Safety of early hospital discharge following admission with ST-elevation myocardial infarction treated with percutaneous coronary intervention: a nationwide cohort study. <i>EuroIntervention</i> , 2022, 17, 1091-1099.	3.2	5
96	Caffeine and incidence of dyspnea in patients treated with ticagrelor. <i>American Heart Journal</i> , 2018, 200, 141-143.	2.7	4
97	Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management: A prespecified subgroup analysis from VALIDATE-SWEDEHEART. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 510-519.	1.0	4
98	Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis. <i>Journal of the American Heart Association</i> , 2021, 10, e020025.	3.7	4
99	Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 6-13.	3.0	3
100	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021, , .	1.2	3
101	Importance of post-approval real-world evidence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 10-11.	3.0	2
102	Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e021115.	3.7	2
103	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 427-429.	3.4	1
104	Individualized Duration of Dual Antiplatelet Therapy Guided by Risk Scoresâ€“ Ready for Prime Time? â€“. <i>Circulation Journal</i> , 2020, 84, 153-155.	1.6	1
105	Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	1
106	Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention. <i>BMJ: British Medical Journal</i> , 2012, 344, e712-e712.	2.3	0
107	Improving long-term outcome after myocardial infarction. <i>Lancet, The</i> , 2012, 380, 1290-1291.	13.7	0
108	Evidenced-Based Antithrombotic Therapy for Acute Coronary Syndromes. <i>Diabetes</i> , 2013, 62, 709-710.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Will CULPRIT-SHOCK change my practice? The CULPRIT-SHOCK trial: culprit lesion-only PCI vs. multivessel PCI in patients with acute myocardial infarction and cardiogenic shock. EuroIntervention, 2018, 14, 955-958.	3.2	0